LivaNova Bicarbon Aortic Valves Receive CE Mark for Expanded Use Labeling with Lower-Dose Blood Thinners in Low-Risk Patients
LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has received CE Mark approval for its Bicarbon ® aortic valves for use with low-dose anticoagulant therapy. The expanded CE labeling means that a lower international normalized ratio (INR), the standardized index used to measure blood coagulability, can be targeted following Bicarbon aortic valve implantation in low-risk1 patients undergoing single bileaflet mechanical aortic valve replacement.
“When choosing a mechanical valve, patients look for a treatment option which lasts for life. The lower INR range approval for LivaNova Bicarbon Aortic Valves means patients now have a greater choice when selecting a mechanical prosthesis, with the freedom to enjoy a more active, confident lifestyle,” said Alistair Simpson, General Manager of LivaNova’s Cardiac Surgery business franchise.
Patients with mechanical heart valves are at risk of blood clot formation (thrombosis and embolism). These patients are placed on lifelong anticoagulant therapy, which can cause side effects, including an increased bleeding risk. After implanting LivaNova Bicarbon aortic heart valves in patients at low risk for thromboembolic events, physicians can now work with a lower-range level of anticoagulant therapy (INR range of 1.5 to 2.5 with 1.9 median target), potentially reducing the risk of bleeding with no increased risk of blood clots.
In more than 25 years of clinical use and up to 17 years of published follow-up2, the Bicarbon family of mechanical valves has shown evidence of a very low incidence of thrombogenicity.
The expanded indication for the Company’s Bicarbon family of aortic heart valves is based on this evidence and the results from the LOWERING-IT trial where patients saw a 60 percent reduction in risk of bleeding3.
“Our experience from the LOWERING-IT trial with nearly 300 patients implanted with Bicarbon aortic valves maintained with an INR close to 1.9, with a median follow-up of over five years was presented at the American Heart Association 2017 meeting in Anaheim, California,” said study lead author Michele Torella, M.D., Ph.D., Department of Cardio-Thoracic and Respiratory Sciences, Monaldi Hospital, Second University of Naples, Naples, Italy. “Our study indicated that the proposed low-INR range between 1.5 and 2.5 (with 1.9 median target) is safe and feasible in low-risk patients after isolated aortic valve replacement with LivaNova’s Bicarbon prosthesis, resulting in similar thrombotic events and in a significant reduction of bleeding occurrence when compared to the conventional anticoagulation regimen.”
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs more than 4,500 employees, inclusive of approximately 900 employed by our CRM business franchise. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.LivaNova.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to LivaNova and assumptions that LivaNova believes to be reasonable, but are inherently uncertain. As a result, LivaNova’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by LivaNova and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond LivaNova’s control.
All information in this news release is as of the date of its release. LivaNova does not undertake or assume any obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this news release.
INR range 1.5-2.5 in patients at low risk for
thromboembolic events undergoing single mechanical aortic valve
2. Single center experience with the Sorin Bicarbon prosthesis: A 17-year clinical follow-up. Celiento et al. - J Thorac Cardiovasc Surg 2014;148:2039-44
3. LOWERing the intensity of oral anticoagulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the “LOWERING-IT” Trial. Torella et al. - Am Heart J 2010;160:171-8
LivaNova PLC Investor Relations and Media
Karen King, +1 (281) 228-7262
Vice President, Investor Relations & Corporate Communications
Deanna Wilke, +1 (281) 727-2764
Corporate External Communications Manager
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
IFF Strengthens Innovation Platform as Partner in Amkiri’s Visual Fragrance™ Technology24.5.2018 23:15 | Tiedote
Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced its partnership in Amkiri’s Visual Fragrance Technology -- a new ‘ink’ that can be drawn on the skin that also delivers a long-lasting fragrance, thus connecting the senses of sight and smell. The innovative product’s launch was announced on March 22, 2018 by Amkiri, an Israeli-based start-up that was founded in 2014. “This is a significant innovation in the fragrance category, merging strong and deeply personal visuals with the resonance and emotion of fragrance,” said IFF Chairman and CEO Andreas Fibig. “The Visual Fragrance technology creates a new platform from which IFF can showcase our capabilities, including naturals, molecules, and cosmetic actives. The potential for innovative applications are nearly endless and our teams are truly inspired by the possibilities.” Amkiri’s patented Visual Fragrance is applied to th
Hisense's Zhou Houjian and Huawei's Kevin Ho to Keynote CES Asia; Focus on Mobility, 5G and Connectivity24.5.2018 18:00 | Tiedote
The Consumer Technology AssociationTM (CTA) today announced that Hisense Chairman Zhou Houjian and Huawei’s president of Handset Product Line Kevin Ho will deliver separate keynote addresses at the upcoming CES AsiaTM 2018. As CES Asia drives the expansion of technology into new areas like artificial intelligence, vehicle technology, AR, VR and more, Chairman Zhou and Mr. Ho will discuss the future of innovation at their respective companies through connectivity and mobility during Asia’s premier tech event. “Hisense and Huawei have become major global brands by challenging the status quo and creating innovative product solutions that engage, entertain and connect consumers around the world,” said Gary Shapiro, president and CEO, CTA. “We are thrilled to welcome Chairman Zhou and Mr. Ho to the CES Asia keynote stage and are eager to learn from these experts who are leading the charge to harness the potential of 5G through various implementation strategies and connection opportunities.”
Maximum Cryptocurrencies Available for EU Traders in Libertex24.5.2018 17:29 | Tiedote
Libertex trading platform, operated by Indication Investments Ltd, announces that starting from May 23rd 2018, European traders can perform operations with 34 new cryptocurrency CFD instruments. This means that Libertex became one of the leading applications and trading platforms for EU traders in terms of amount of cryptocurrencies available. Andrew Nikolaev, Libertex Executive director highlighted: “Cryptocurrencies are one of the main trends in financial industry for the past couple of years. The demand for these assets grows significantly. We are happy to satisfy the demand of European traders for new innovative crypto-instruments launching them in our cutting edge Libertex platform”. Launch of cryptocurrency pairs in Libertex for EU traders follows Circular from Cyprus financial regulator - CySec issued on May 15th 2018, that introduces new rules for governing derivatives on virtual currencies. According to this Circular, CFDs on virtual currencies are considered as financial inst
Andersen Global’s Middle East Expansion Continues with Solutions Bridge in Kuwait24.5.2018 16:30 | Tiedote
Solutions Bridge, an Accounting and Corporate Secretarial Services firm in Kuwait City, has signed a Collaboration Agreement with Andersen Global. The addition of a location in Kuwait demonstrates Andersen Global’s growth in the Middle East, which is a significant market for the organization. “Having a strong practice in Kuwait is important to our regional success and this is an extraordinary opportunity to continue providing best-in-class services globally,” commented Mark Vorsatz, Global Chairman and Andersen Tax LLC CEO. “There are many changes in the Middle East currently and the development of tax laws is a major factor in the region. The addition of Solutions Bridge, one of the largest accounting firms in Kuwait, positions us for continued opportunities for expansion.” Formed by former professionals of Andersen in Kuwait, Solutions Bridge is led by Partner Fouad Al Hourani. The firm provides accounting and corporate secretarial services for both individuals and corporations in a
Workiva Signs OEM Agreement with SAP to Offer SAP® Cloud Platform Integration with the Workiva Wdesk Platform24.5.2018 16:00 | Tiedote
Workiva (NYSE:WK), a leader in cloud-based data collaboration, reporting and compliance solutions, today announced it has signed an original equipment manufacturer (OEM) agreement with SAP (NYSE:SAP). Through this agreement, Workiva is partnering with SAP to provide a first-party integration with the Wdesk platform using the SAP® Cloud Platform Integration service. The bundled solutions are expected to provide customers with powerful linking, auditability and control features. “Today’s announcement demonstrates that Workiva and SAP are committed to providing customers with a rich integration experience,” said Matt Rizai, chairman and CEO of Workiva. “Through our OEM partnership, we will help customers all over the world improve the value of their business data.” After users integrate their SAP business data directly into the Wdesk platform, they can benefit from the full capabilities of Wdesk, including synchronized data, dynamic commentary, controlled collaboration, granular permissio
M-Brain Appoints New CEO24.5.2018 15:25 | Tiedote
M-Brain, a global leader in market and media intelligence solutions, has appointed Christian Cedercreutz Chief Executive Officer as of 13.8.2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180524005676/en/ M-Brain, a global leader in market and media intelligence solutions, has appointed Christian Cedercreutz Chief Executive Officer as of 13.8.2018. (Photo: Business Wire) Christian holds a Master of Economics degree from Hanken School of Economics in Helsinki. His career has been built with IBM over the past 20 years, in which he has held various management positions in five different European countries. Christian brings strong consultative selling experience and has over the years worked across the IBM Corporation in roles such as leading global client relationships, and leading SW and HW technology businesses in Finland. His most recent role has been to lead the cognitive SW solutions (Watson) business in Finland. Simu
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme